Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 9/20 | 0.65 |
| ▸ | MPC2 | O95563 | 1/20 | 0.56 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 10/20 | 0.54 |
| ▸ | PPARA | Q07869 | 6/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3370792 | 0.92 | PPARG (0.62) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL501421 | 0.91 | PPARG (0.61) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL4622433 | 0.91 | PPARG (0.57) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL1130792 | 0.81 | PPARG (0.54) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL4165069 | 0.80 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL6064786 | 0.80 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL2906120 | 0.79 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL5319250 | 0.79 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL143498 | 0.79 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Rivoglitazone SCHEMBL6064788 | 0.78 | PPARG (0.98) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | claimed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | claimed |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-01-19 | — | — | US | disclosed |
| EP-3323818-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2018-05-23 | — | — | EP | disclosed |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-03-06 | — | — | US | disclosed |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | ARENA PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| EP-2619198-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-07-31 | — | — | EP | disclosed |
| WO-2013055910-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | WO | disclosed |
| EP-2556056-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | Arena Pharmaceuticals, Inc. (US) | 2013-02-13 | — | — | EP | disclosed |
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| WO-2012170702-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| WO-2012145361-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| WO-2012135570-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| WO-2012040279-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2012-03-29 | — | — | WO | disclosed |
| WO-2011127051-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | WO | disclosed |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1607103-A1 | CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE | Eisai Co., Ltd. (JP) | 2005-12-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | PPARG 85/4885MPC2 416/4885CYP2C8 1506/4885 |
| US-20210340133-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, SLC5A2 | PPARG 46/4885MPC2 212/4885CYP2C8 1961/4885 |
| US-20060177444-A1 | Concomitant drug as therapeutic agent for inflammatory bowel disease | PPARG, PPARA, NR3C1 | PPARG 1/4885MPC2 2895/4885CYP2C8 1517/4885 |
| US-20140051629-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, GLP1R, DPP4 | PPARG 45/4885MPC2 202/4885CYP2C8 1631/4885 |
| US-10894787-B2 | Modulators of the GPR119 receptor and the treatment of disorders related thereto | GPR119, GLP1R, DPP9 | PPARG 56/4885MPC2 252/4885CYP2C8 1764/4885 |
| US-20140066369-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GLP1R, SLC5A2 | PPARG 60/4885MPC2 317/4885CYP2C8 2672/4885 |
| US-20140018371-A1 | Modulators Of The GPR119 Receptor And The Treatment Of Disorders Related Thereto | GPR119, GCGR, GLP1R | PPARG 86/4885MPC2 735/4885CYP2C8 1997/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.